DIOC LogoDIOIC




MEDICAL TRIAL



Control Group-Non Gastrointestinal Ailment


TOXICITY

Aggregate Base-Line

EFFICIENCY

Aggregate Base-Line

EFFICASY

Aggregate Base-Line


CONDITIONS


Emesis or Vomitting

Aggregate Base-Line

Pain and General Discomfort

Aggregate Base-Line

Food Stuck and Backed-Up through windpipe and Esophagus

Aggregate Base-Line

Belching

Aggregate Base-Line

Cough

Aggregate Base-Line


Gastrointestinal Ailments - particular to EoE, GERD AND Ulcer

Without Saniprazole Utilization but on other Medicines of particulars.


TOXICITY

Aggregate Base-Line

EFFICIENCY

Aggregate Base-Line

EFFICASY

Aggregate Base-Line


CONDITIONS


Emesis or Vomitting

Aggregate Base-Line

Pain and General Discomfort

Aggregate Base-Line

Food Stuck and Backed-Up through windpipe and Esophagus

Aggregate Base-Line

Belching

Aggregate Base-Line

Cough

Aggregate Base-Line


Gastrointestinal Ailments - Particular to EOE, GERD AND Ulcer on SANIPRAZOLE!


Initial Trial - Concentration Levels in Graduation - 0.0675 MG, 3MG in Combinatory 200MG Ibuprofen.

Initial Comprehensive Trial - Concentration Levels - 100MG and 100MG Formulation Development.

Comprehensive Trial - Comprehensive Trial Levels - 50MG and 50MG Formulation Trial.

Duration Start - June, 2022.

Relief: Instant.


TOXICITY OF SANIPRAZOLE

Aggregate Base-Line

EFFICIENCY OF SANIPRAZOLE

Aggregate Base-Line

EFFICASY OF SANIPRAZOLE

Aggregate Base-Line


CONDITIONS


Emesis or Vomitting

Aggregate Base-Line

Pain and General Discomfort

Aggregate Base-Line

Food Stuck and Backed-Up through windpipe and Esophagus

Aggregate Base-Line

Belching

Aggregate Base-Line

Cough

Aggregate Base-Line